Ms. Lee Siu Fong joined the Group in April 1997 and has since been responsible for the Group’s financial affairs. She is an entrepreneur and had since 1992 established and run several companies with primary responsibility in financial affairs.

Ms. Leelalertsuphakun Wanee joined the Group in April 1997. She was appointed the Chief Marketing & Sales Officer in September 2003 and has been responsible for the Group’s sales and marketing activities since then.

Dr. Li Xiaoyi holds a PhD in Pharmacology from the University of Illinois at Chicago and was a postdoctoral fellow with Parke-Davis Research Division of Warner-Lambert company in the United States. He is an Honourary Fellow and Adjunct Professor at the Hong Kong University of Science and Technology. He was appointed as a member of the Chinese People’s Political Consultative Conference of Anhui Province in China in January 2018. He is the founder of the Group and has been responsible for the daily operations and research and development of the Group since 1994 to April 2021. He has been re-designated to a non-executive director of the Company and serve as a senior adviser to the Company on 29 April 2021.

Mr. James Charles Gale joined the Board on 2 January 2022. He obtained a master’s degree in Business Administration from the University of Chicago. He is the co-founder and managing director of Signet Healthcare Management LLC, a private equity firm based in New York City. Founded in 1998, the firm provides growth equity to commercial-stage life sciences companies. He serves on the board of directors of a number of Signet portfolio companies including Advantice Health LLC, Ascendia Pharmaceuticals Inc, Bionpharma Inc (Chairman), Chr Olesen Synthesis A/S, Leon-nanodrugs GmbH, Pharmaceutics International, Inc and RK Pharma Inc. He is also on the board of two public companies: Knight Therapeutics Inc (TSX: GUD) and Hyloris Pharmaceuticals SA (Euronext: HYL).

Dr. Chan Yau Ching, Bob joined the independent Board on 14 January 2002. He has extensive experience in corporate development and financial management of high-growth companies. He had been a finance professor, researcher and consultant. He had also served directorship at various listed and privately held companies in Hong Kong and in the United States. He was appointed as the independent non-executive director of Hangzhou Huaxing Chuangye Communication Technology Co., Ltd., which is a listed company on the Shenzhen Stock Exchange, from December 2018 to November 2020. Currently, he is the managing director of KBR Capital Limited, a company engaged in advising clients on management and investment activities in China and Hong Kong. He is also the independent non-executive director of China High Speed Transmission Equipment Group Co., Ltd. and Daisho Microline Holdings Limited, which are listed companies on the Main Board of The Stock Exchange of Hong Kong Limited.

Ms. Cheang Yee Wah, Eva joined the independent Board on 17 May 2023. She has been Founder Holdings Limited’s company secretary (stock code: 0418) since 2018. She received a Bachelor of Business Administration from The University of Hong Kong and a Master of Finance (Corporate Finance) from The Hong Kong Polytechnic University. She is a Chartered Financial Analysts Charterholder, a member of The Hong Kong Institute of Certified Public Accountants and an associate member of The Hong Kong Chartered Governance Institute. She has over 20 years of experience in financial management, including 10 years of experience in accounting, finance, audit and corporate finance with an international audit firm and listed companies in Hong Kong.

Dr. Tsim Wah Keung, Karl joined the independent Board on 20 September 2004. He currently serves as Chair Professor of Life Science at the Hong Kong University of Science and Technology. He holds a Bachelor of Science degree and a Master degree in Biochemistry from The Chinese University of Hong Kong, and a Doctorate in Molecular Neurobiology from the University of Cambridge. He has published numerous articles in biological sciences and traditional Chinese medicines. He also serves in several local committees in advising the development of traditional Chinese medicine as health food products.